A Phase III multicenter, randomized, double-blind, placebo-controlled study in China to evaluate the efficacy and safety of naldemedine in adult patients with opioid-induced constipation (OIC) who were receiving opioid analgesic therapy
Latest Information Update: 05 Jun 2025
At a glance
- Drugs Naldemedine (Primary)
- Indications Constipation
- Focus Therapeutic Use
Most Recent Events
- 05 Jun 2025 New trial record
- 30 May 2025 According to Shionogi media release, company announced that based on the results of this trial, the New Drug Application (NDA) for naldemedine a treatment for opioid-induced constipation (OIC), has been accepted in China.